Hyloris Pharmaceuticals SA

ENXTBR:HYL Stock Report

Market Cap: €148.4m

Hyloris Pharmaceuticals Management

Management criteria checks 3/4

Hyloris Pharmaceuticals' CEO is Stijn Van Rompay, appointed in Jan 2024, has a tenure of less than a year. total yearly compensation is €212.82K, comprised of 89.7% salary and 10.3% bonuses, including company stock and options. directly owns 36.67% of the company’s shares, worth €54.42M. The average tenure of the management team and the board of directors is 2.1 years and 4.9 years respectively.

Key information

Stijn Van Rompay

Chief executive officer

€212.8k

Total compensation

CEO salary percentage89.7%
CEO tenureless than a year
CEO ownership36.7%
Management average tenure2.1yrs
Board average tenure4.9yrs

Recent management updates

Recent updates

Here's Why We're Not Too Worried About Hyloris Pharmaceuticals' (EBR:HYL) Cash Burn Situation

Dec 21
Here's Why We're Not Too Worried About Hyloris Pharmaceuticals' (EBR:HYL) Cash Burn Situation

Here's Why We're Not Too Worried About Hyloris Pharmaceuticals' (EBR:HYL) Cash Burn Situation

Aug 04
Here's Why We're Not Too Worried About Hyloris Pharmaceuticals' (EBR:HYL) Cash Burn Situation

Hyloris Pharmaceuticals (EBR:HYL) Is In A Strong Position To Grow Its Business

Dec 28
Hyloris Pharmaceuticals (EBR:HYL) Is In A Strong Position To Grow Its Business

Do Institutions Own Hyloris Pharmaceuticals SA (EBR:HYL) Shares?

Mar 08
Do Institutions Own Hyloris Pharmaceuticals SA (EBR:HYL) Shares?

CEO Compensation Analysis

How has Stijn Van Rompay's remuneration changed compared to Hyloris Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-€13m

Mar 31 2024n/an/a

-€14m

Dec 31 2023€213k€191k

-€15m

Compensation vs Market: Stijn's total compensation ($USD222.06K) is below average for companies of similar size in the Belgian market ($USD633.86K).

Compensation vs Earnings: Insufficient data to compare Stijn's compensation with company performance.


CEO

Stijn Van Rompay (48 yo)

less than a year

Tenure

€212,820

Compensation

Mr. Stijn Van Rompay is a Co-Founder and Chief Executive Officer of Hyloris Pharmaceuticals SA and serves as its Director since 2020. He was the Chief Executive Officer of Alter Pharma, a high-growth pharm...


Leadership Team

NamePositionTenureCompensationOwnership
Stijn Van Rompay
Co-Founderless than a year€212.82k36.67%
€ 54.4m
Thomas Jacobsen
Co-Founderless than a yearno data13.78%
€ 20.4m
Jean-Luc Vandebroek
Chief Financial Officer3.3yrsno data0.032%
€ 47.7k
Dietmar Aichhorn
Chief Operating Officer4.2yrsno data0.12%
€ 172.3k
Sven Watthy
Investor Relations Manager & Communications managerno datano datano data

2.1yrs

Average Tenure

48.5yo

Average Age

Experienced Management: HYL's management team is considered experienced (2.1 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Stijn Van Rompay
Co-Founder4.9yrs€212.82k36.67%
€ 54.4m
Thomas Jacobsen
Co-Founder4.9yrsno data13.78%
€ 20.4m
Stefan Yee
Chairman of the Board4.9yrs€22.50kno data
Leon Van Rompay
Non-Executive Director4.9yrs€12.50kno data
Marc Foidart
Independent Director4.9yrs€22.50kno data
Vincent Dessel
Independent Directorless than a yearno datano data
Revital Rattenbach
Independent Directorless than a yearno datano data

4.9yrs

Average Tenure

49yo

Average Age

Experienced Board: HYL's board of directors are considered experienced (4.9 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 10:19
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Hyloris Pharmaceuticals SA is covered by 5 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Beatrice AllenBerenberg
Laura RobaDegroof Petercam
David SeynnaeveDegroof Petercam